by Cell Transplantation
Scientists have developed an advanced therapy medicinal product (ATMP) that aims to protect leukemia patients against tumor relapse and potentially fatal infection following haploidentical...
by Translational Oncology
Researchers believe development of chimeric antigen receptor (CAR) T cells targeting the C-X-C chemokine receptor type 4 (CXCR4) could play a role in treating both acute myeloid leukemia (AML) and...
by Transplantation and Cellular Therapy
Clinical study evidence indicates that toxic effects and infections associated with chimeric antigen receptor (CAR) T-cell therapy are leading contributors to non-relapse mortality (NRM) in...
by Transplantation and Cellular Therapy
Researchers report that outpatient (OP) administration of axicabtagene ciloleucel (axi-cel) is a viable alternative to inpatient (IP) delivery of the chimeric antigen receptor (CAR) T-cell therapy...
by Science Translational Medicine
Investigators designed chimeric antigen receptor (CAR) T cells to work against vascular endothelial growth factor A (VEGF), a protein that contributes to immunosuppressive tumor microenvironments...
by Blood
Scientists have identified CSF-1R blockade combined with lenalidomide maintenance therapy as a promising pathway to better progression-free survival following autologous stem cell transplantation...